Alzheimer's disease: Have we opened the Golden Gate to disease-modifying therapy?
作者信息
Isaacs Jeremy D
机构信息
Department of Neurology, Atkinson Morley Regional Neuroscience Centre, St George's University Hospitals NHS Foundation Trust, London SW17 0QT, United Kingdom.
Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, United Kingdom.
出版信息
Cereb Circ Cogn Behav. 2022 Dec 17;6:100156. doi: 10.1016/j.cccb.2022.100156. eCollection 2024.
Abstract
摘要
相似文献
1
Alzheimer's disease: Have we opened the Golden Gate to disease-modifying therapy?阿尔茨海默病：我们是否已打开通往疾病修饰疗法的金门？
Cereb Circ Cogn Behav. 2022 Dec 17;6:100156. doi: 10.1016/j.cccb.2022.100156. eCollection 2024.
2
Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.社论：阿尔茨海默病的疾病修饰治疗靶点，包括淀粉样 β 和tau 蛋白。
Med Sci Monit. 2021 Jul 26;27:e934077. doi: 10.12659/MSM.934077.
3
Synthetic DNA Assembly Using Golden Gate Cloning and the Hierarchical Modular Cloning Pipeline.利用 Golden Gate 克隆和分层模块化克隆管道进行合成 DNA 组装。
Curr Protoc Mol Biol. 2020 Mar;130(1):e115. doi: 10.1002/cpmb.115.
4
Highly Efficient Single-Pot Scarless Golden Gate Assembly.高效单锅无痕金门组装
ACS Synth Biol. 2019 May 17;8(5):1047-1054. doi: 10.1021/acssynbio.8b00480. Epub 2019 Apr 30.
5
[Melatonin agonist: a possible disease-modifying agent for Alzheimer's disease].褪黑素激动剂：一种可能用于阿尔茨海默病的疾病修饰药物
Nihon Rinsho. 2012 Feb;70(2):349-52.
6
Reimagining cholinergic therapy for Alzheimer's disease.重新构想胆碱能疗法治疗阿尔茨海默病。
Brain. 2022 Jul 29;145(7):2250-2275. doi: 10.1093/brain/awac096.
7
High-Complexity One-Pot Golden Gate Assembly.高通量一步法 Golden Gate 组装。
Curr Protoc. 2023 Sep;3(9):e882. doi: 10.1002/cpz1.882.
8
An efficient cloning method to expand vector and restriction site compatibility of Golden Gate Assembly.一种高效的克隆方法，用于扩展 Golden Gate Assembly 的载体和限制酶切位点兼容性。
Cell Rep Methods. 2023 Aug 22;3(8):100564. doi: 10.1016/j.crmeth.2023.100564. eCollection 2023 Aug 28.
9
Simple and Efficient Modification of Golden Gate Design Standards and Parts Using Oligo Stitching.寡核苷酸拼接法对 Golden Gate 设计标准和元件的简单高效修饰。
ACS Synth Biol. 2022 Jun 17;11(6):2214-2220. doi: 10.1021/acssynbio.2c00072. Epub 2022 Jun 8.
10
Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的染色质修饰化合物的潜力。
Pathobiol Aging Age Relat Dis. 2012;2. doi: 10.3402/pba.v2i0.14980. Epub 2012 Feb 20.
引用本文的文献
1
Editorial. : The journal at age 5.社论：该期刊创刊五周年
Cereb Circ Cogn Behav. 2024 Sep 7;7:100368. doi: 10.1016/j.cccb.2024.100368. eCollection 2024.
本文引用的文献
1
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.确立阿尔茨海默病导致轻度认知障碍临床试验中常用结局评估的临床有意义变化。
J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102.
2
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
3
Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults.老年人认知障碍和痴呆的血管病理学及发病机制。
Cereb Circ Cogn Behav. 2022 Jun 30;3:100148. doi: 10.1016/j.cccb.2022.100148. eCollection 2022.
4
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.阿尔茨海默病中的高清除率抗淀粉样蛋白免疫疗法。第1部分：疗效和安全性数据的荟萃分析与综述以及医学经济学方面
Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.
5
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.度胺能减少淀粉样蛋白后与 tau 病理和临床结局的关联：TRAILBLAZER-ALZ 随机临床试验。
JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793.
6
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
7
Brain volume loss due to donanemab.多奈单抗导致的脑容量损失。
Eur J Neurol. 2021 Sep;28(9):e67-e68. doi: 10.1111/ene.15007. Epub 2021 Jul 16.
8
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
9
Biomarkers for dementia: too soon for routine clinical use.痴呆症的生物标志物：常规临床应用时机尚早。
Lancet Neurol. 2020 Nov;19(11):884-885. doi: 10.1016/S1474-4422(20)30365-3.
10
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.《痴呆症的预防、干预与照护：柳叶刀委员会2020年报告》
Lancet. 2020 Aug 8;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6. Epub 2020 Jul 30.
Zotero 插件